An update from InspireMD (NSPR) is now available.
InspireMD, Inc. has announced that the one-year follow-up results from its C-GUARDIANS U.S. clinical trial will be presented at the upcoming LINC 2024 conference. The findings are significant for stakeholders as they could influence the company’s standing in the medical device sector. The press release detailing these results is now available, potentially impacting the company’s stock and investor interest.
See more insights into NSPR stock on TipRanks’ Stock Analysis page.
